Good morning, everyone, and welcome to the first quarter 2025 results presentation. And it's with great pride and joy that we present this report.
In fact, I think it's probably the best report we have presented, possibly with the exception of one or two COVID-boosted pandemic reports. But in terms of the broad business, it is definitely the best report we have published since we listed the company now eight years ago.
It's a combination of factors. You know, we see continued strong top-line growth. Organic growth was more than 14%. And most importantly, the further down the profit and loss statement you go, the more operational leverage you observe coming through in margins. Expanding EBITDA margin up 1.6 percentage points, EBIT margin up 2.4 percentage points. And, you know, it continues as you flow down through the profit and loss statement, which is exactly what we have been focused on. It is exactly what we have been reporting to you over the past 4 or 5 quarters. It is just that as the numbers get bigger, it becomes a bit more pronounced. And that's really what we see here. Uh, you know, Poland continues to be really very strong in healthcare services. Uh, now, India had a particularly weak quarter. And we'll speak a little bit more about that later on. But I think it's noteworthy to see that we pushed through these results, both in growth and margin expansion. Despite, actually, you can argue, a disappointing quarter out of one of our core markets, we still saw significant growth. So more about that a bit later. Diagnostics are very strong. Again, I remind you that half of diagnostics is in Germany, where a good chunk of that is public reimbursement, and we receive no price compensation. But despite that, with all the initiatives going on and actually really strong growth in the German private pay revenue and really good performance outside of Germany, in DX, we see really good growth, double-digit organic growth out of DX as well as margin expansion.
Now that's flowing through, as you've seen in the last quarters in really good cash generation cash flow. You know we've always had good cash flow. It's just that the numbers start to get bigger, so the amounts become larger. And then also, I'm really very pleased and happy to be able to report to you that on a quarterly basis, i.e.
We annualized the first quarter, we have. Achieved the year-end 2025 financial targets that we set a little bit more than two years ago.
So we're on an annualized basis.
We're trading on around €2.3 billion of organic revenue.
We're just a tad above 350 million organic adjusted EBITDA. And we're also trading above those two additional targets.
We added a year ago, adjusted EBITDA of at least 235 million and EBIT of at least 140 million. So that's after nine quarters out of 12.
So, three quarters of the period.
And for all of those that attended our Capital Markets Day, I think you very well remember that they were certainly not unambitious targets.
I believe that demonstrates a super performance. Then, if you go on to our standard graphic pages.
The revenue split is quite typical.
What's worthwhile to point out there?
You see, Poland has now grown into 52% of revenue on the back of its stellar growth performance over a longer period of time. You see 22% growth out of Poland, 7% out of Germany, which is not bad, in fact, because there is relatively no price growth and relatively little volume growth in the public pay segment. So the private pay segment is growing really well, with a 19% increase out of Romania.
And you see basically a flattish 1% out of India. And I take the opportunity to comment on that here.
Now, India had a strange first quarter. Uh, we were trading pretty much on plan in January and the first week of February. And then it was pretty much a cliff fall for the second half of February and March.
And I think most people in India experienced the same thing.
So very weak consumer sentiment.
Then we have around 10% of medical tourism in our business in India, and we got no visas issued. So that sort of came to a halt. We closed down one underperforming unit, etc.
. So there were a number of factors explaining that fact. But, you know, there's no other way of expressing the first quarter in India than it was a disappointment. Now, I think the most important of all is that it was an exceptional quarter.
Now April is pretty much over, like tomorrow, and we are back and trading with significant double-digit revenue growth again in April, which we expect to continue going forward, which is important. So. So that is India. We then flip on to the perfect slide.
We're very pleased with how the volume growth is translating into higher margins and consequently increased profitability. So EBITDA up to 86.5 million, 29% growth, and even 15% margin, showing good growth, 150 basis points on last year. And the adjusted number is above 90 million for the first time. So 90.6 million adjusted EBITDA, 15.7%. So good. Strong number, adjusted EBITDAaL up over 60 million. I think also, for the first time, effectively.
And then I only mention EBIT is almost doubling, not fully doubling, but not far from it, from 19 up to 36 million, so a margin of 6.2%. So significant margin expansion.
And again, very healthy.
Good cash flow.
And then of course, the biggest expansion, if you wish, comes on EPS, obviously, because it's the smallest number. So EPS more than tripling effectively from just above €0.04 to above €0.13.
So I think it's a super, super performance.
Then if you go to healthcare services, there is good growth running above 400 million, I think for the first time.
So 403 million of revenue, 18% up of which 15% was organic and just short of 9% of that being price.
So, I remind you that price is very important to us, ensuring we can continue to implement price growth to manage our operations effectively. Although, you know, cost inflation has certainly come down and we are in a much better position than a couple of years ago.
But one should also be very clear on the fact that it's not gone.
So it's not normalized.
So it's really important that we are able to keep ensuring that we can continue to raise pricing, although at lower levels than what was seen last year. So fee-for-service here is half of the division, up 14%. And I made the point before that. You know, performance is pretty much stellar across everything we do in, uh, in Poland. Uh, it is also good actually out of Romania, relatively speaking, compared to last year, we still have loss-making units in the large hospital in Bucharest.
But you know, Romania is pushing on. I have commented on India. The member growth may appear somewhat soft. I remind you that, as we announced at the end of last year, we are exiting the Hungarian business, and as we do that, it happens gradually throughout the first six months of the year. So we had a not insignificant negative member movement out of Hungary as part of that exit process here in the first quarter, which contributed quite significantly to that lower than normal member growth number. If we then switch to the earnings profile for healthcare services, we see strong margin expansion, in fact, super strong margin expansion.
You see EBITDA up more than two percentage points, a bit even more. 2.3 percentage points, a bit, uh. Significantly more than doubling in terms of absolute amounts and almost also doubling in terms of the margin you see.
3.4 to 6.7. So lots of operational leverage is coming through here.
And I remind you this is despite the Indian business, which is significant in this division, not firing on all cylinders in this particular quarter. So there's still room to improve this situation significantly as we progress.
You actually see that in this next bullet point where we have reported that a number of times. Now, when we take the six most immature hospitals, five of them being in India and one of them being the large recent addition in Bucharest, you see that we had an EBITDA loss for the quarter of 3.9 million. Effectively, that's 600,000 worse than in the prior quarter, which is purely driven by the point I made on India. In fact, Romania is improving the situation. So the loss is coming out of the Indian hospitals due to lower revenue than we had in the prior quarter. But again, I reiterate that's going to reverse into the second quarter.
So you don't need to worry about that going forward. But one should recognize that in this quarter, the medical cost ratio is the most important cost category in this business, i.e. All of the cost of delivering the medical service, you see, is actually down quite significantly, by two percentage points, which is a combination of factor mix, price growth, and a lot of very good hard work by our management team to manage utilization and costs. You have the standard Indian picture. Nothing has changed in that since we showed this the last quarter.
Now we have to remind you we have two more units coming up in India over the coming 12 months. Both of them in the main Hyderabad market. So one will open in the summer. Both of them are large units.
And the second one will open towards the end of the year or beginning of 2026.
Then, flipping to diagnostic services again, I made the point before about the good revenue growth and strong momentum in this business. 182 million.
So just short of 12%. Almost all of it being organic growth, with the price component just above 3% of this, which is slightly less than half of the price component in healthcare services. Again, you have heard me say many times before, that's explained by the fact that half of this business is in Germany, where there's very little price compensation.
So basically, outside Germany, we have been able to adjust prices very much in line with how healthcare services have been able to do. So, good performance pretty much across all markets here, really.
You see a relatively benign growth in lab tests.
We have done fewer. If you remember, last year we conducted a significant number of nearly free lab tests in Ukraine for the public insurance house. We still do some of those tests, but we did significantly fewer this quarter, which explains the much lower lab test growth vis-à-vis revenue growth. Fee-for-service here accounts for a full 70% of the division, and it was up 16%. I remind you, we talked a lot about the end of last year about the pricing reform, the additional pricing reform, I should say, that came into force in Germany in January.
We have assumed a worst-case scenario for us, and that's what we are accounting for. We will know in early July how the different Länder CVS treat this.
And it may be that we get some upside.
Time will tell.
At least we know it's not going to get any worse than what we are assuming currently in our numbers.
You can also see a little bit of what I'm talking about on these two pie charts to the right, where you see the upper pie chart, you see Germany is growing 6% and below.
You see, public funding is increasing by 3%. And basically pretty much all of that public money is in Germany. So that means that the other half of the 6% growth in Germany is actually experiencing a 12% growth rate, if you see what I mean.
So that illustrates the fact that our private pay German business is actually growing very nicely.
Now, this resulted in a good flow-through to increased profitability. So EBITDA performed very well, showing a significant increase. So, a bit more than one percentage point, just short of a 20% margin. EBITDA, likewise, just short of a 16% margin. And EBIT then grew a bit more. So a margin of just above 12%, up 28%. So, uh, good results came out of this. Uh, and again, it's not split out here, but I think I made that comment last quarter around.
I can make that comment again that actually, Germany, where there's a lot of focus, obviously on this price reform, etc.
. Our total German business in diagnostics is growing its margins. So relative to the first quarter last year, despite all the pressures around us, we are up around one percentage point in terms of the German margin.
Then we have two post-closing events that we just want to comment on. We made two acquisitions that we had sort of hinted to you about before in the previous quarter; these closed just early in April. Both of them had been in competition clearance for quite some time. So we were very happy when they finally got released. In diagnostics, you may be familiar with the relatively large lab group, SYNLAB Group, that used to be listed in Germany. Now, again, it's a private company, and they are selling off a number of assets. And we had an opportunity to pick up this set of markets, and this is really a synergy play for us. So we have tremendous synergies, particularly in Romania but also in Turkey. And then they have some really nice businesses in some of the other markets there in the Balkans.
But you can see that we stated in the release that we expect, already within one year, to have grown their current profitability by at least 50%. And within at least two years we'll have doubled the current profitability levels from synergies, really. So we feel we have all of that under control. So we believe this is a very good, very strategic, and certainly very accretive acquisition for our shareholders. Then in healthcare services, we build further on the tremendous growth and positioning we have in Poland by adding a very well-run fitness operator to our network.
And then I remind you, you know, we sell these sports cards in Poland alongside our healthcare cards to the B2B corporate clients. And then they are buying either standalone healthcare. They may be buying standalone sports, but increasingly they are buying a mix of the two, which is really what we want, because, of course, the more customers also go and look after themselves at the gym, the healthier they become, so the less illness they will contract. And hence the synergies are both in distribution and cost for us.
So we expect this to be a very good acquisition. We think it's priced reasonably. We will have good synergies on the overlap that I was just talking about, and it also will be very accretive to our results. And with that, I think I hand over to Anand for the Financial Review.